Interpreting differences in quality of life: The FACT-H&N in laryngeal cancer patients

Quality of Life Research

Volumn 13, Issue 4, 2004, Pages 725-733

  Ringash, Jolie ^a,c   Bezjak, Andrea ^a,c   O'Sullivan, Brian ^a,c   Redelmeier, Donald A ^b,c  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Laryngeal neoplasms; Minimal important difference; Quality of life; Questionnaires

Indexed keywords

ADULT; AGED; CANCER LOCALIZATION; CANCER PATIENT; CONFERENCE PAPER; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FUNCTIONAL ASSESSMENT OF CANCER THERAPY; GENDER; HEAD AND NECK CARCINOMA; HUMAN; LARYNX CARCINOMA; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PREDICTION; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; SELF CONCEPT; STATISTICAL SIGNIFICANCE;

AGED; ANALYSIS OF VARIANCE; CANCER CARE FACILITIES; CARCINOMA, SQUAMOUS CELL; DATA INTERPRETATION, STATISTICAL; FEMALE; HUMANS; INTERVIEWS; LARYNGEAL NEOPLASMS; MALE; MIDDLE AGED; ONTARIO; PSYCHOMETRICS; QUALITY OF LIFE; QUESTIONNAIRES; SICKNESS IMPACT PROFILE;

EID: 1942505868     PISSN: 09629343     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:QURE.0000021703.47079.46     Document Type: Conference Paper

References (28)

1. National Cancer Institute of Canada. Canadian Cancer Statistics 1997. National Cancer Institute of Canada, 1997.
2. Sobin LH, Wittekind Ch, eds. International Union Against Cancer TNM Classification of Malignant Tumours. 5th ed. New York: John Wiley & Sons, 1997: 33-37.
3. Finizia C, Geterud A, Holmberg E, et al. Advanced laryngeal cancer T3-T4 in Sweden: A retrospective study (1986-1990) - survival and locoregional control related to treatment. Acta Otolaryngol (Stockh) 1996; 116: 906-912.
4. Forestiere AA, Berkey B, Maor M, et al. Phase III trial to preserve the larynx: Induction chemotherapy and radiotherapy versus concomitant chemoradiotherapy versus radiotherapy alone, Intergroup trial R91-11 [abst]. Proc Am Soc Clin Oncol (ASCO), San Francisco; J Clin Oncol 2001; 20: 2a.
5. The Department of Veterans' Affairs Laryngeal Cancer Study Group. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med 1991; 324: 1685-1690.
6. Guyatt GH, Feeny D, Patrick D. Proceedings of the international conference on the measurement of quality of life as an outcome in clinical trials: Postscript. Controlled Clin Trials 1991; 12: 266S-269S.
7. Liang MH. Evaluating measurement responsiveness. J Rheumatol 1995; 22: 1191-1192.
8. Lydick E, Epstein RS. Interpretation of quality of life changes. Qual Life Res 1993; 2: 221-226.
9. Jaeschke R, Singer J, Guyatt GH. Measurement of Health Status: Ascertaining the minimal clinically important difference. Control Clin Trials 1989; 10: 407-415.
10. Wright JG. The minimal important difference: Who's to say what is important? J Clin Epidemiol 1996; 49: 1221-1222.
11. Ringash J, Bezjak A. A structured review of quality of life instruments for head and neck cancer patients. Head Neck 2001; 23: 201-213.
12. D'Antonio LL, Zimmerman GJ, Cella DF, et al. Quality of life and functional status measures in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg 1996; 122: 482-487.
13. Cella DF, Tulsky DS, Gray G, et al. The functional assessment of cancer therapy scale: Development and validation of the general measure. J Clin Oncol 1993; 11(3): 570-579.
14. Karnofsky DA, Burchenal JH. The clinical evaluation of chemotherapeutic agents in cancer. In: Macleod CM (ed.), Evaluation of Chemotherapeutic Agents. New York: Columbia University Press, 1949: 191-205.
15. Redelmeier DA, Guyatt GH, Goldstein RS. Assessing the minimal important difference in symptoms: A comparison of two techniques. J Clin Epidemiol 1996; 49: 1215-1219.
16. Juniper EF, Guyatt GH, Willan A, et al. Determining a minimal important change in a disease-specific quality of life questionnaire. J Clin Epidemiol 1994; 47: 81-87.
17. Osoba D, Rodrigues G, Myles J, et al. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 1998; 16: 139-144.
18. Redelmeier DA, Lorig K. Assessing the clinical importance of symptomatic improvements: An illustration in rheumatology. Arch Intern Med 1993; 153: 1337-1342.
19. Wells GA, Tugwell P, Kraag GR, et al. Minimum important difference between patients with rheumatoid arthritis: The patient's perspective. J Rheumatol 1993; 20: 557-560.
20. Redelmeier DA, Goldstein RS, Min ST, et al. Spirometry and dyspnea in patients with COPD: when small differences mean little. Chest 1996; 109: 1163-1168.
21. Redelmeier DA, Bayoumi AM, Goldstein RS, et al. Interpreting small differences in functional status: The six minute walk test in chronic lung disease patients. Am J Respir Crit Care Med 1997; 155: 1278-1282.
22. Moses LE. Think and Explain with Statistics. Reading, Massachusetts: Addison Wesley 1986: 336-338.
23. Ringash J, Redelmeier D, O'Sullivan B, Bezjak A. Quality of life and utility in irradiated laryngeal cancer patients. Int J Rad One Biol Phys 2000; 47: 875-881.
24. List MA, D'Antonio LL, Cella DF, et al. The Performance Status Scale for Head and Neck Cancer Patients and the Functional Assessment of Cancer Therapy - Head and Neck scale. Cancer 1996; 77: 2294-2301.
25. Cella D, Hahn EA, Dineen K. Meaningful change in cancer-specific quality of life scores: Differences between improvement and worsening. Qual Life Res 2002; 11: 207-221.
26. Cella DF. Manual of the Functional Assessment of Chronic Illness Therapy (FACIT) Scales. Centre on Outcomes, Research and Education (CORE), Evanston: Northwestern Healthcare and Northwestern University, 1997.
27. Brant R. Sutherland L, Hilsden R. Examing the minimum important difference. Stat Med 1999; 18: 2593-2603.
28. Weinstein ND. Optimistic biases about personal risks. Science 1989; 246: 1232-1233.